Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 8/2016

01.05.2016 | Adis Drug Evaluation

Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia

verfasst von: Lesley J. Scott

Erschienen in: Drugs | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Azacitidine (Vidaza®) is a pyrimidine nucleoside analogue of cytidine and is approved in the EU for use in patients with higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML), including older patients (aged ≥65 years) with AML with >30 % bone marrow blasts (BMB) who are ineligible for haematopoietic stem cell transplant. This article reviews the clinical efficacy and tolerability of azacitidine in the treatment of these patient populations, as well as summarizing its pharmacological properties. In pivotal, international, phase 3 trials, subcutaneous azacitidine was an effective and well tolerated treatment in patients with higher-risk MDS or AML, including older patients with AML with >30 % BMB, with extensive evidence from the real-world setting confirming its efficacy and safety in these patient populations. Azacitidine is the only approved hypomethylating agent that has been shown to prolong overall survival compared with conventional care regimens and thus, it is recommended as the first-line hypomethylating agent for most patients with higher-risk MDS. Hence, azacitidine remains and important agent for use in the treatment of higher-risk MDS and AML, including in older patients with AML with >30 % BMB.
Literatur
1.
Fenaux P, Haase D, Sanz GF, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii57–69.CrossRefPubMed
2.
3.
Fey MF, Buske C, on behalf of the ESMO Guidelines Working Group. Acute myelodysplastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi138–43.CrossRefPubMed
4.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia: rationale and important changes. Blood Cancer J. 2009;114(5):937–51.CrossRef
5.
Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88.PubMed
6.
Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.CrossRefPubMedPubMedCentral
7.
8.
Santini V, Prebet T, Fenaux P, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res. 2014;38(12):1381–91.CrossRefPubMed
9.
10.
Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324–41.PubMed
11.
Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448–58.CrossRefPubMedPubMedCentral
12.
13.
Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2012;72(8):1111–36.CrossRefPubMed
14.
15.
16.
Grovdal M, Karimi M, Tobiasson M, et al. Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation. Leukemia. 2014;28(2):411–3.CrossRefPubMed
17.
Follo MY, Finelli C, Mongiorgi S, et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA. 2009;106(39):16811–6.CrossRefPubMedPubMedCentral
18.
Momparler RL, Momparler LF, Samson J, et al. Comparison of the antileukemic activity of 5-AZA-2′-deoxycytidine, 1-β-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res. 1984;8(6):1043–9.CrossRefPubMed
19.
Bernstein I, Byun HM, Mohrbacher A, et al. A phase I biological study of azacitidine (Vidaza) to determine the optimal dose to inhibit DNA methylation. Epigenetics. 2010;5(8):750–7.CrossRefPubMed
20.
Hagemann S, Heil O, Lyko F, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011;6(3):e17388.CrossRefPubMedPubMedCentral
21.
Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019–28.CrossRefPubMed
22.
Cluzeau T, Robert G, Mounier N, et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget. 2012;3(4):490–501.CrossRefPubMedPubMedCentral
23.
Valencia A, Masala E, Rossi A, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014;28(3):621–8.CrossRefPubMedPubMedCentral
24.
Laille E, Goel S, Mita AC, et al. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous azacitidine and its pharmacokinetics in patients with severe renal impairment. Pharmacotherapy. 2014;34(5):440–51.CrossRefPubMed
25.
Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005;23(17):3906–11.CrossRefPubMed
26.
Marcucci G, Silverman L, Eller M, et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with myelodysplastic syndromes. Clin Pharmacol. 2013;46(5):597–602.
27.
Uchida T, Ogawa Y, Kobayashi Y, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci. 2011;102(9):1680–6.CrossRefPubMed
28.
Chen Y, Liu L, Laille E, et al. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. Cancer Chemother Pharmacol. 2010;65(5):995–1000.CrossRefPubMedPubMedCentral
29.
Laille E, Xiao Z, Du X, et al. Pharmacokinetics (PK) of subcutaneous (SC) azacitidine (AZA) in Chinese subjects with higher-risk myelodysplastic syndromes (HR-MDS) from a phase II, open-label study. Conference Abstract. 2015.
30.
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10):2429–40.CrossRefPubMed
31.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.CrossRefPubMedPubMedCentral
32.
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–9.CrossRefPubMedPubMedCentral
33.
Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244–9.CrossRefPubMedPubMedCentral
34.
Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010;76(3):218–27.CrossRefPubMedPubMedCentral
35.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9.CrossRefPubMed
36.
Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011;117(12):2697–702.CrossRefPubMedPubMedCentral
37.
Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013;98(7):1067–72.CrossRefPubMedPubMedCentral
38.
Seymour JF, Bennett JM, List AF, et al. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. Br J Haematol. 2014;165(1):49–56.CrossRefPubMed
39.
Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia with >30% bone marrow blasts and <15 G/L white blood cell count: results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data [abstract]. Blood. 2015;126(23):2515.
40.
van der Helm LH, Veeger NJ, Kooy M, et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30 % bone marrow blasts. Leuk Res. 2013;37(8):877–82.CrossRefPubMed
41.
van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol. 2011;155(5):599–606.CrossRefPubMed
42.
Bernal T, Martinez-Camblor P, Sanchez-Garcia J, et al. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015;29(9):1875–81.CrossRefPubMed
43.
Dinmohamed AG, van Norden Y, Visser O, et al. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015;. doi:10.​1038/​leu.​2015.​220.
44.
Voso MT, Niscola P, Piciocchi A, et al. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. Eur J Haematol. 2016;96(4):344–51.CrossRefPubMed
45.
Douvali E, Papoutselis M, Vassilakopoulos TP, et al. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. Leuk Res. 2013;37(8):889–93.CrossRefPubMed
46.
Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer. 2012;118(4):1014–22.CrossRefPubMed
47.
Pleyer L, Burgstaller S, Girschikofsky M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol. 2014;93(11):1825–38.CrossRefPubMedPubMedCentral
48.
Smith BD, Beach CL, Mahmoud D, et al. Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol. 2014;3:19.CrossRefPubMedCentral
49.
Minetto P, Guolo F, Clavio M, et al. Azacytidine therapy in previously untreated elderly AML patients: comparison with conventional chemotherapy in a matched-paired analysis [abstract no. E942]. Haematologica. 2015;100(Suppl 1):376–7.
50.
Pleyer L, Stauder R, Burgstaller S, et al. Azacitidine in patients with WHO-defined AML: results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol. 2013;6:32.CrossRefPubMedPubMedCentral
51.
Bories P, Bertoli S, Berard E, et al. Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network. Am J Hematol. 2014;89(12):E244–52.CrossRefPubMed
52.
Pleyer L, Germing U, Sperr WR, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38(4):475–83.CrossRefPubMed
53.
Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in patients with treatment-related acute myeloid leukemia: retrospective analysis of the Austrian Azacitidine Registry [abstract]. Blood. 2014;124(21):2284.
54.
Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia: comparison of patients with AML-MRF Vs AML-NOS enrolled in the Austrian Azacitidine Registry [abstract]. Blood. 2014;124(21):3681.
55.
Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in patients with acute myeloid leukemia: impact of intermediate-risk vs high-risk cytogenetics on patient outcomes [abstract]. Blood. 2014;124(21):955.
56.
Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in patients with relapsed/refractory acute myeloid leukemia: retrospective analysis of the Austrian Azacitidine Registry [abstract]. Blood. 2014;124(21):943.
57.
Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–11.CrossRefPubMed
58.
Moon JH, Kim SN, Kang BW, et al. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol. 2010;89(7):681–9.CrossRefPubMed
59.
Falantes JF, Trujillo P, Piruat JI, et al. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(4):236–44.CrossRefPubMed
60.
Alhan C, Westers TM, van der Helm LH, et al. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. Cytometry B Clin Cytom. 2014;86(3):207–15.CrossRefPubMed
61.
Abaigar M, Ramos F, Benito R, et al. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. Ann Hematol. 2013;92(11):1543–52.CrossRefPubMed
62.
Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007;21(9):1937–44.CrossRefPubMed
63.
Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–52.CrossRefPubMed
64.
Sanna A, Gozzini A, Raugei G, et al. Influence of bone marrow fibrosis on response of INT-2/high risk MDS patients to 5-azacitidine [abstract no. P279]. Haematologica. 2015;100(Suppl 3):165.
65.
Improta S, Della Cioppa P, Lucania A, et al. Iron chelation therapy improves haematological response in high-risk myelodysplastic patients treated with azacitidine [abstract no. P123]. Haematologica. 2015;100(Suppl 3):103–4.
66.
Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840–5.CrossRefPubMedPubMedCentral
67.
Ramos F, Thepot S, Pleyer L, et al. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res. 2015;39(3):296–306.CrossRefPubMed
68.
Breccia M, Loglisci G, Cannella L, et al. Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response. Leuk Lymphoma. 2012;53(5):985–6.CrossRefPubMed
69.
Tran HT, Kim HN, Lee IK, et al. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome. J Korean Med Sci. 2011;26(2):207–13.CrossRefPubMedPubMedCentral
70.
Cluzeau T, Mounier N, Karsenti J-M, et al. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine. Am J Hematol. 2013;88(9):780–3.CrossRefPubMed
71.
Seymour JF, Silverman LR, Döhner H, et al. The safety and tolerability of azacitidine (AZA) are comparable in patients with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS) [abstract]. Blood. 2015;126(23):3754.
72.
Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130–8.PubMedPubMedCentral
73.
74.
Ishikawa T. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndromes. Int J Clin Oncol. 2014;19(1):10–5.CrossRefPubMed
75.
76.
Fenaux P, Seymour JF, Santini V, et al. Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. Leuk Res. 2014;38(2):258–62.CrossRefPubMed
Metadaten
Titel
Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia
verfasst von
Lesley J. Scott
Publikationsdatum
01.05.2016
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 8/2016
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0585-0

Weitere Artikel der Ausgabe 8/2016

Drugs 8/2016 Zur Ausgabe

Current Opinion

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Therapy in Practice

Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Therapy in Practice

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Adis Drug Evaluation

Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia

Adis Drug Evaluation

Gabapentin Enacarbil: A Review in Restless Legs Syndrome

AdisInsight Report

Ixekizumab: First Global Approval